Molecular Formula | C21H13F3N2O4 |
Molar Mass | 414.33 |
Density | 1.49±0.1 g/cm3(Predicted) |
Melting Point | 165-167°C |
Boling Point | 534.6±50.0 °C(Predicted) |
Flash Point | 277.1°C |
Solubility | Chlorform (Slightly), DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 1.67E-11mmHg at 25°C |
Appearance | Solid |
Color | Off-White to Pale Yellow |
Maximum wavelength(λmax) | ['287nm(CHCl3)(lit.)'] |
Merck | 14,9044 |
pKa | 2.72±0.10(Predicted) |
Storage Condition | Store at +4°C |
Stability | Acid Sensitive, Moisture Sensitive |
Refractive Index | 1.625 |
Physical and Chemical Properties | White to pale yellow crystalline powder. |
Use | As a non-steroidal anti-inflammatory analgesic, it can be used for the adjuvant treatment of fibrous cyst and asthma |
RTECS | QT2999200 |
Toxicity | LD50 orally in rats: 12000 mg/kg (Los) |
biological activity | Talniflumate (MSI-1995) is an anti-inflammatory agent in the treatment of cystic fibrosis, it is used as a mucin modulator in chronic obstructive pulmonary disease and asthma. Talniflumate is also a human Calcium-activated chloride channel. |
Target | IC50: Ca 2 -activated Cl-channel (CaCC) |
Animal Model: | CF mice with distal intestinal obstructive syndrome (DIOS) |
Dosage: | 0.4 mg/g |
Administration: | Oral chow; 21 days |
Result: | Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. |
Use | Tamoxifen is a non-steroidal anti-inflammatory and analgesic drug substance, and can be used for the adjuvant treatment of fibrous cysts and asthma. |